Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Michael B Wohlfeiler"'
Autor:
Gerald Pierone, Jennifer S. Fusco, Laurence Brunet, Vani Vannappagari, Supriya Sarkar, Cassidy E. Henegar, Jean van Wyk, Michael B. Wohlfeiler, Anthony Mills, Gregory P. Fusco
Publikováno v:
AIDS Research and Therapy, Vol 21, Iss 1, Pp 1-10 (2024)
Abstract Background Two-drug regimens (2DRs) have been introduced in recent years to potentially reduce antiretroviral therapy (ART) toxicities and drug-drug interactions while demonstrating comparable efficacy to three-drug regimens (3DRs) for peopl
Externí odkaz:
https://doaj.org/article/343e25b329694831a85014e48c8789a0
Autor:
Michael B. Wohlfeiler JD, MD, AAHIVS, Laurence Brunet PhD, Quateka Cochran MSNEd, RN, ACRN, Jennifer S. Fusco BS, Ricky K. Hsu MD, Gregory P. Fusco MD, MPH
Publikováno v:
Journal of the International Association of Providers of AIDS Care, Vol 23 (2024)
Background We evaluated the impact of the CHORUS™ app on adherence to the cabotegravir and rilpivirine long-acting injectable (CAB + RPV LAI) monthly injections schedule. Methods Healthcare centers (HCCs) were randomized to access CHORUS™ CAB + R
Externí odkaz:
https://doaj.org/article/373de538ddf54574bd0ff245f657eb90
Autor:
Michael G. Sension, Laurence Brunet, Ricky K. Hsu, Jennifer S. Fusco, Quateka Cochran, Christine Uranaka, Gayathri Sridhar, Vani Vannappagari, Jean Van Wyk, Lewis McCurdy, Michael B. Wohlfeiler, Gregory P. Fusco
Publikováno v:
Infectious Diseases and Therapy, Vol 12, Iss 12, Pp 2807-2817 (2023)
Abstract Introduction The first complete long-acting antiretroviral therapy (ART) regimen, cabotegravir + rilpivirine long-acting (CAB + RPV LA) injectable, was approved in the US for HIV-1 treatment in individuals on a stable antiretroviral regimen
Externí odkaz:
https://doaj.org/article/4d491b7ec6474e8391338563f1ac2e28
Autor:
Michael B. Wohlfeiler, Rachel Palmieri Weber, Laurence Brunet, Jennifer S. Fusco, Christine Uranaka, Quateka Cochran, Monica Palma, Tammeka Evans, Carl Millner, Gregory P. Fusco
Publikováno v:
BMC Primary Care, Vol 23, Iss 1, Pp 1-8 (2022)
Abstract Background Sustained, routine care is vital to the health of people with HIV (PWH) and decreasing transmission of HIV. We evaluated whether the identification of PWH at-risk of falling out of care and prompts for outreach were effective in r
Externí odkaz:
https://doaj.org/article/02cacf5a919b41b091d90b74a94ef6e6
Autor:
Anthony M. Mills, Laurence Brunet, Jennifer S. Fusco, Michael B. Wohlfeiler, Cindy P. Garris, Alan K. Oglesby, Joseph M. Mrus, Philip C. Lackey, Gregory P. Fusco
Publikováno v:
Infectious Diseases and Therapy, Vol 9, Iss 1, Pp 41-52 (2019)
Abstract Introduction Dolutegravir (DTG), Elvitegravir (EVG), Raltegravir (RAL) and Darunavir (DRV) are commonly prescribed core agents for antiretroviral therapy (ART), and a need exists to compare their clinical effectiveness, as defined by virolog
Externí odkaz:
https://doaj.org/article/776bda721e7f4713a0838d8a28b00c64
Autor:
Michael G Sension, Ricky K Hsu, Jennifer S Fusco, Laurence Brunet, Quateka Cochran, Christine Uranaka, Gayathri Sridhar, Vani Vannappagari, Andrew Zolopa, Jean A van Wyk, Lewis McCurdy, Gregory P Fusco, Michael B Wohlfeiler
Publikováno v:
Open Forum Infectious Diseases. 9
Background The first long-acting (LA) antiretroviral therapy (ART) regimen, cabotegravir+rilpivirine (CAB+RPV) injection, was approved by the FDA in January 2021 for ART-experienced, people with HIV (PWH) with undetectable viral load (VL< 50 copies/m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b80c88edfc1eb88ad7845740513a94eb
https://doi.org/10.1093/ofid/ofac492.105
https://doi.org/10.1093/ofid/ofac492.105
Autor:
Michael B Wohlfeiler, Rachel P Weber, Laurence Brunet, Javeed Siddiqui, Michael Harbour, Amy L Phillips, Brooke Hayward, Jennifer S Fusco, Ricky K Hsu, Gregory P Fusco
Publikováno v:
Open Forum Infectious Diseases. 9
Background HIV-associated wasting (i.e., progressive, involuntary weight loss with both fat and lean tissue loss; HIVAW) is an under-appreciated AIDS-defining illness; the 2012-2018 period prevalence was reported as 18% in a recent claims study in th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5bad3ad78a57a66260bdb412d39f7693
https://doi.org/10.1093/ofid/ofac492.516
https://doi.org/10.1093/ofid/ofac492.516
Autor:
Cindy P, Garris, Maggie, Czarnogorski, Marybeth, Dalessandro, Ronald, D'Amico, Toyin, Nwafor, Will, Williams, Deanna, Merrill, YuanYuan, Wang, Larissa, Stassek, Michael B, Wohlfeiler, Gary I, Sinclair, Leandro A, Mena, Blair, Thedinger, Jason A, Flamm, Paul, Benson, William R, Spreen
Publikováno v:
Journal of the International AIDS Society. 25
The CUSTOMIZE hybrid III implementation-effectiveness study evaluated implementation of once-monthly long-acting (LA) cabotegravir + rilpivirine in diverse US healthcare settings. Here, we report patient participant perspectives after 12 months in CU
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1771ebb01ec7de370146e12aec53d4f5
https://doi.org/10.1002/jia2.26006
https://doi.org/10.1002/jia2.26006
Autor:
Maggie Czarnogorski, Cindy P. Garris, Marybeth Dalessandro, Ronald D'Amico, Toyin Nwafor, Will Williams, Deanna Merrill, YuanYuan Wang, Larissa Stassek, Michael B. Wohlfeiler, Gary I. Sinclair, Leandro A. Mena, Blair Thedinger, Jason A. Flamm, Paul Benson, William R. Spreen
Publikováno v:
Journal of the International AIDS Society. 25(9)
CUSTOMIZE evaluated the implementation of long-acting (LA) cabotegravir + rilpivirine, a novel healthcare provider-administered injectable antiretroviral therapy regimen, in diverse US healthcare settings. Findings from staff-study participants (SSPs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75c3f99c110b0ce2e9fdbb34994f5299
https://pubmed.ncbi.nlm.nih.gov/36094142
https://pubmed.ncbi.nlm.nih.gov/36094142
Autor:
Patrick W G Mallon, Laurence Brunet, Jennifer S Fusco, Girish Prajapati, Andrew Beyer, Gregory P Fusco, Michael B Wohlfeiler
Publikováno v:
Open Forum Infectious Diseases
Background Increases in lipids have been observed in people with HIV (PWH) switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF). We assessed changes in low-density lipoprotein cholesterol (LDL-C) and triglycerides (TG) fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25445eabf3788309cd12c9866bcaa6a2
https://doi.org/10.1093/ofid/ofab621
https://doi.org/10.1093/ofid/ofab621